DIVISLAB9,415.00

Divi's Laboratories Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersLAURUSLABSCOHANCEGLANDTORNTPHARMZYDUSLIFEMAXHEALTHDRREDDYCIPLAMcap ₹2.49L Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations1,909.01,855.02,303.02,118.02,338.02,319.02,585.02,410.02,715.02,604.02,831.03,080.0
Other Income86.095.079.079.0106.082.086.0119.0145.088.0155.064.0
Total Income1,995.01,950.02,382.02,197.02,444.02,401.02,671.02,529.02,860.02,692.02,986.03,144.0
Expenses
+ Cost of Materials Consumed711.0794.0898.0893.0976.01,021.0931.01,010.0937.01,217.01,214.01,503.0
+ Purchases of Stock-in-Trade0.00.06.00.00.00.00.00.00.00.00.00.0
+ Changes in Inventories99.0-65.0-2.0-40.0-7.0-99.050.0-54.0136.0-272.0-95.0-517.0
+ Employee Benefit Expense266.0268.0297.0292.0304.0297.0350.0340.0354.0367.0381.0408.0
+ Finance Costs1.00.02.00.01.00.01.03.08.06.06.06.0
+ Depreciation & Amortisation95.095.095.097.099.099.0107.0112.0113.0118.0120.0133.0
+ Other Expenses354.0369.0373.0351.0349.0357.0368.0385.0400.0402.0397.0431.0
Total Expenses1,526.01,461.01,669.01,593.01,722.01,675.01,807.01,796.01,948.01,838.02,023.01,964.0
EBITDA479.0489.0731.0622.0716.0743.0886.0729.0888.0890.0934.01,255.0
EBIT384.0394.0636.0525.0617.0644.0779.0617.0775.0772.0814.01,122.0
Profit
PBT before Exceptional Items469.0489.0713.0604.0722.0726.0864.0733.0912.0854.0963.01,180.0
+ Exceptional Items0.00.00.00.00.00.00.00.00.0-74.00.00.0
Pretax Income469.0489.0713.0604.0722.0726.0864.0733.0912.0780.0963.01,180.0
+ Current Tax107.0122.0160.0179.0218.0174.0228.0191.0220.0208.0249.0291.0
+ Deferred Tax14.09.015.0-5.0-6.0-37.0-26.0-3.03.0-11.0-37.0-13.0
Tax Expense121.0131.0175.0174.0212.0137.0202.0188.0223.0197.0212.0278.0
Net Income348.0358.0538.0430.0510.0589.0662.0545.0689.0583.0751.0902.0
+ Net Income — Continuing Ops348.0358.0538.0430.0510.0589.0662.0545.0689.0583.0751.0902.0
+ Other Comprehensive Income1.05.0-7.01.01.01.00.03.03.016.0-1.02.0
Total Comprehensive Income349.0363.0531.0431.0511.0590.0662.0548.0692.0599.0750.0904.0
Net Income to Common348.0358.0538.0430.0510.0589.0662.0545.0689.0583.0751.0902.0
Per Share
Basic EPS13.1113.5020.2516.2019.2022.2024.9320.4925.9721.9828.3133.95
Diluted EPS13.1113.5020.2516.2019.2022.2024.9320.4925.9721.9828.3133.95
Other Comprehensive Income — detail
+ Other Comprehensive Income0.03.03.016.0-1.02.0
+ Items NOT to be Reclassified to P&L1.01.0-5.0-1.00.0-1.0-1.0-1.00.017.0-8.02.0
+ Tax on Items NOT to be Reclassified0.00.00.04.0-2.01.0
+ Tax on Items NOT to be Reclassified — alt tag0.00.0-2.00.00.0-1.0
+ Items to be Reclassified to P&L0.05.0-4.02.02.01.01.04.05.04.07.01.0
+ Tax on Items to be Reclassified0.00.02.01.02.00.0
+ Tax on Items to be Reclassified — alt tag0.01.00.00.01.00.0
Comprehensive Income — Owners of Parent349.0363.0531.0431.0511.0590.0662.0548.0692.0599.0750.0904.0
Per Share — as-filed variants
Basic EPS — Continuing Operations13.1113.5020.2516.2019.2022.2024.9320.4925.9721.9828.3133.95
Diluted EPS — Continuing Operations13.1113.5020.2516.2019.2022.2024.9320.4925.9721.9828.3133.95
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit1,099.01,126.01,401.01,265.01,369.01,397.01,604.01,454.01,642.01,659.01,712.02,094.0
Gross Margin %57.5760.7060.8359.7358.5560.2462.0560.3360.4863.7160.4767.99
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)469.0489.0713.0604.0722.0726.0864.0733.0912.0854.0963.01,180.0
− Exceptional Items (reconciliation)0.00.00.00.00.00.00.00.00.0-74.00.00.0
Net Income Adj (tax-effected)348.0358.0538.0430.0510.0589.0662.0545.0689.0638.3751.0902.0
EPS Adj13.1113.5020.2516.2019.2022.2024.9320.4925.9724.0728.3133.95
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.002.002.002.002.002.002.002.00
Paid Up Equity Capital53.053.053.053.053.053.053.053.053.053.053.053.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.